Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
05 févr. 2018 08h45 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:...
Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models
22 janv. 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio’s synthetic vaccine approach using a collection of synthetic DNA...
Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016
17 janv. 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder; and Dr. Jian Yan, the company’s Lead...
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
09 janv. 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approachesEngages the Parker Institute’s extensive...
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
08 janv. 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called...
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
02 janv. 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187)...
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
11 déc. 2017 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has promoted Dr. Laurent Humeau to Senior Vice President, Research & Development, reporting to...
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
06 déc. 2017 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Wendy Yarno has been elected to the company's Board of Directors. Wendy Yarno...
Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
29 nov. 2017 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100...
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
27 nov. 2017 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase)...